> For the complete documentation index, see [llms.txt](https://docs.escher.finance/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://docs.escher.finance/key-features/injection-protocol.md).

# Injection Protocol

### &#x20;Introduction

At Escher, we’ve always believed that **Liquid Staking Tokens (LSTs)** must go beyond just locking assets. An LST only has value if it can **interact with DeFi**, generate **real yield**, and **outperform vanilla staking**.

But how do you ensure that increased **TVL in a DEX**, lending protocol, or LP pool actually translates into better returns for your LST holders?

Today, we’re excited to unveil the answer: **The Injection Protocol** — Escher’s native mechanism to **capture DeFi yield** and return it directly into the staking economy, increasing APR **without inflating token supply**.

***

### &#x20;The Concept

Escher is deploying **strategic positions across various DeFi protocols** using its chain-abstracted LST design. Because Escher operates **cross-chain**, we can build flexible strategies that extract real yield — not just speculative points farming.

While point systems are trending, they’re unpredictable and often controlled by internal team discretion. Escher is focused on something more sustainable: **real token flows** and **predictable APR** directly into your eBABY position.

***

### &#x20;How It Works

1. **Escher opens a strategic position** (e.g., LP on Tower, lending on Euler, etc.)
2. Escher collects protocol fees (usually in **BABY**)
3. Escher **injects those BABY fees back into the staking vault, without minting new eBABY**
4. Resulting in a boost in **value of each eBABY**

This creates a **positive feedback loop** between the DeFi protocol and the eBABY token:

> Higher DeFi usage → more fees → more BABY injected → higher eBABY value → more staking demand.

***

### Technical Structure

#### 1. **eBABY Valuation Model**

Each eBABY is backed by a pool of staked BABY tokens.

$$
p = \frac{B}{S}
$$

Where:

* \= total BABY backing
* $$S$$= total eBABY supply
* $$p$$= value of one eBABY

***

#### 2. **Monthly BABY Injection**

Each month, Escher injects an additional amount of BABY () into the staking vault, **without minting new eBABY**:

$$
p\_{new}= \frac{B + \Delta B}{S}
$$

This increases the value of each eBABY over time — boosting user APR without token inflation.

***

#### 3. **Impact on APR**

The APR from injection alone:

$$
APR\_{injection} = \frac{12 \times \Delta B}{S}
$$

Where:

* $$\Delta B$$= Monthly BABY added to the vault
* $$S$$= Total eBABY supply

And total APR becomes:

$$
APR\_{total} = APR\_{\text{staking}} + APR\_{\text{injection}}
$$

***

### &#x20;Why This APR Model Is Unique

In typical staking systems, APR decreases as more tokens are staked:

$$
$APRchain=\frac{\text{Inflation}}{\text{Staking Ratio}}
$$

More stakers → smaller piece of the pie.

**But Escher’s Injection Protocol breaks that pattern.**

The injected rewards come from **external DeFi strategies**, not the chain’s inflation or validator pool. This means:

* The injected BABY is **not split proportionally** by staked supply.
* It's added **directly to the vault** without minting new eBABY.
* More capital does **not reduce APR**, and might even **increase it**, if the strategies scale efficiently.

#### 🔁 Real Yield, Not Just Inflation

This mechanism creates **non-dilutive APR**:

* It doesn’t rely on new token issuance
* It’s not capped by on-chain inflation curves
* It’s fueled by real usage and strategy performance (e.g. LP fees, lending yield)

This leads to one of the core benefits of the Injection Protocol:

> More TVL → more DeFi activity → more fees → more BABY injections → higher APR.

Not the other way around.

***

### 🌐 Why It Matters

This model makes **holding eBABY more rewarding than native staking**, while maintaining decentralized infrastructure and avoiding token inflation. It’s **fully composable**, **chain-abstracted**, and **aligned with real usage** — not speculative hype.

***

###
